Leaflet: Munitions of War Employment and Remuneration: No. 594. Pamphlets. Munitions. 1918. MUN. V/13. Book.
1918 - Gale Group | ArchivesUnbound Women-War
Miscellaneous Free eBooks
Patricia Chastagner, Frida Loría, Jessica Vargas, Josh Tois, Marc I. Diamond, George Okafo, Christel Brou, Chiara Zurzolo,
... heparin, purified by ultracentrifugation, and labeled with ATTO 594. The quality of the assembled fibrils was checked ... this figure. Figure EV1. Spreading of K18-ATTO 594 fibrils and of DID Quality control of K18 ... of CAD cells, first challenged with K18-ATTO 594 fibrils, trypsinized 24 h later, and replated for ... experiments, *P = 0.011). Spreading of K18-ATTO 594 fibrils in SH-SY5Y cells. Quantification by flow cytometry of the percentage of K18-ATTO 594-positive acceptor cells after coculture of donor and ...
Tópico(s): Neuroscience and Neuropharmacology Research
2020 - Springer Nature | EMBO Molecular Medicine
Abyssinia Expeditionary Force IOR/L/MIL/5/594
0000 - Gale Group | NCCO EuropeAfrica
Chiara Cremolini, Maria Di Bartolomeo, Alessio Amatu, Carlotta Antoniotti, Roberto Moretto, Rosa Berenato, Federica Perrone, Elena Tamborini, Giuseppe Aprile, Sara Lonardi, Andrea Sartore‐Bianchi, Gabriella Fontanini, Massimo Milione, Calogero Lauricella, Salvatore Siena, Alfredo Falcone, Filippo de Braud, Fotios Loupakis, Filippo Pietrantonio,
... is well established, the impact of BRAF codons 594 and 596 mutations, occurring in <1% of CRCs, ... and molecular features and prognosis of BRAF codons 594 and 596 mutant mCRCs, compared with BRAF V600E ... 59, 61, 117 and 146 and BRAF codon 594, 596 and 600 mutational status, as detected by ... were included. Results Ten patients bearing BRAF codons 594 or 596 mutated tumors were identified and compared ... right-sided, mucinous and with peritoneal spread, BRAF 594 or 596 mutated were more frequently rectal, nonmucinous ...
Tópico(s): Genetic factors in colorectal cancer
2015 - Elsevier BV | Annals of Oncology
Abyssinia Expeditionary Force IOR/L/MIL/5/594 Financial report.
0000 - Gale Group | NCCO EuropeAfrica
To investigate serum PC-594 fatty acid levels as a potential biomarker in North American pancreatic cancer (PaC) patients, and to compare its performance to ... Using tandem mass spectrometry, we evaluated serum PC-594 levels from 84 North American patients with confirmed ... receiver-operator characteristic (ROC) curve analysis, and PC-594 correlation with age and CA19-9 determined by regression analysis.Mean PC-594 levels were 3.7 times lower in PaC ... μmol/L. There was no correlation between PC-594 and age, disease stage or gender (P > 0. ...
Tópico(s): Pancreatitis Pathology and Treatment
2015 - Baishideng Publishing Group | World Journal of Gastroenterology
Abyssinia Expeditionary Force IOR/L/MIL/5/594
0000 - Gale Group | NCCO EuropeAfrica
Andrés E. Perez Bay, Ryan Schreiner, Francesca Mazzoni, José María Carvajal-González, Diego Gravotta, Emilie Perret, Gullermo Lehmann Mantaras, Yuan‐Shan Zhu, Enrique Rodriguez‐Boulan,
... spectrofluorometry analysis (Supplementary Figure S2A). The specificity of 594-Tf for dog TfR was confirmed by colocalization ... AP-1B KD MDCK cells incubated basolaterally with 594-Tf for 15 min displayed strong colocalization of 594-Tf with immunostained rab11a at ARE, which typically ... Figure 2A, column 4). In contrast, basolaterally internalized 594-Tf was not detected in ARE in WT ... showed that the percentage of rab11a colocalizing with 594-Tf increased from 0±0.1% in WT ... 001) (Figure 2A′ top). Accordingly, the percentage of 594-Tf colocalizing with rab11a increased from 0±0. ...
Tópico(s): Microtubule and mitosis dynamics
2013 - Springer Nature | The EMBO Journal
Abyssinia Expeditionary Force IOR/L/MIL/5/594
0000 - Gale Group | NCCO EuropeAfrica
Jeong Heo, Caroline J. Breitbach, Anne Moon, Chang Won Kim, Rick Patt, Mi Kyung Kim, Yu Kyung Lee, Sung Yong Oh, Hyun Young Woo, Kelley A. Parato, Julia L. Rintoul, Theresa Falls, Theresa Hickman, Byung-Geon Rhee, John C. Bell, David H. Kirn, Tae-Ho Hwang,
JX-594 is a targeted and granulocyte-macrophage colony stimulating factor (GM-CSF) expressing oncolytic poxvirus designed to selectively ... specific immunity. In a phase 1 trial, JX-594 injection into hepatocellular carcinoma (HCC) was well-tolerated ... perfusion, and tumor necrosis. We hypothesized that JX-594 and sorafenib, a small molecule inhibitor of B- ... HCC cell lines were uniformly sensitive to JX-594. Anti-raf kinase effects of concurrent sorafenib inhibited JX-594 replication in vitro, whereas sequential therapy was superior ...
Tópico(s): Immunotherapy and Immune Responses
2011 - Elsevier BV | Molecular Therapy
Abyssinia Expeditionary Force IOR/L/MIL/5/594
0000 - Gale Group | NCCO EuropeAfrica
Kelley A. Parato, Caroline J. Breitbach, Fabrice Le Bœuf, Jiahu Wang, Chris Storbeck, Carolina S. Ilkow, Jean‐Simon Diallo, Theresa Falls, Joseph K. Burns, Vanessa da Silva Garcia, Femina Kanji, Laura Evgin, Kang Hu, Francois Paradis, Shane Knowles, Tae-Ho Hwang, Barbara C. Vanderhyden, Rebecca C. Auer, David H. Kirn, John C. Bell,
... the basis of a single genetic mutation. JX-594 is a thymidine kinase (TK) gene-inactivated oncolytic ... cell lysis and stimulation of antitumoral immunity. JX-594 has demonstrated a favorable safety profile and reproducible ... well described. We analyzed the replication of JX-594 in three model systems: primary normal and cancer cells, surgical explants, and murine tumor models. JX-594 replication, transgene expression, and cytopathic effects were highly ... selective, and broad spectrum activity was demonstrated. JX-594 cancer-selectivity was multi-mechanistic; replication was activated ...
Tópico(s): Cancer Research and Treatments
2011 - Elsevier BV | Molecular Therapy
Abyssinia Expeditionary Force IOR/L/MIL/5/594
0000 - Gale Group | NCCO EuropeAfrica
Tae-Ho Hwang, Anne Moon, James M. Burke, Antoni Ribas, Joe Stephenson, Caroline J. Breitbach, Manijeh Daneshmand, Naomi De Silva, Kelley A. Parato, Jean‐Simon Diallo, Yeon-Sook Lee, Ta‐Chiang Liu, John C. Bell, David H. Kirn,
JX-594 is a targeted and granulocyte macrophage-colony stimulating factor (GM-CSF)-expressing oncolytic poxvirus designed to selectively ... study the mechanisms-of-action (MOA) of JX-594 in humans, a mechanistic proof-of-concept clinical ... subsets such as neutrophils (25–300% increase). JX-594 replication and subsequent shedding into blood was detectable ... after cycles 1–9. Tumor biopsies demonstrated JX-594 replication, perivascular lymphocytic infiltration, and diffuse tumor necrosis. ... the most common adverse events. In sum, JX-594 replication, oncolysis, and expression of both transgenes were ...
Tópico(s): Immunotherapy and Immune Responses
2011 - Elsevier BV | Molecular Therapy
Abyssinia Expeditionary Force IOR/L/MIL/5/594
0000 - Gale Group | NCCO EuropeAfrica
Michael C. Rowbotham, Rachel W. Duan, James W. Thomas, Wolfram Nothaft, Misha-Miroslav Bačkonja,
ABT-594 is a neuronal nicotinic acetylcholine receptor (NNR) agonist that exhibits potent analgesic activity in preclinical models of ... evaluate the safety and analgesic efficacy of ABT-594 in patients with diabetic peripheral neuropathic pain (DPNP). ... 1:1:1:1 to receive placebo, ABT-594 150 microg BID, ABT-594 225 microg BID, or ABT-594 300 microg BID. Patients were titrated to a fixed-dose of ABT-594 over 7 days and remained at this dose ... 6 weeks. Compared to placebo, all three ABT-594 treatment groups showed significantly greater decreases on the ...
Tópico(s): Cholinesterase and Neurodegenerative Diseases
2009 - Lippincott Williams & Wilkins | Pain
Abyssinia Expeditionary Force IOR/L/MIL/5/594 List.
0000 - Gale Group | NCCO EuropeAfrica
Byeong-Ho Park, Tae-Ho Hwang, Ta‐Chiang Liu, Daniel Y. Sze, Jae‐Seok Kim, Hyuk‐Chan Kwon, Sung Yong Oh, Sang-Young Han, Jin-Han Yoon, Sook Hee Hong, Anne Moon, Kelly Speth, Chohee Park, Young-Joo Ahn, Manijeh Daneshmand, Byung Geon Rhee, Herbert M. Pinedo, John C. Bell, David H. Kirn,
Summary Background JX-594 is a targeted oncolytic poxvirus designed to selectively replicate in and destroy cancer cells with cell-cycle abnormalities and ... We aimed to assess intratumoral injection of JX-594 in patients with refractory primary or metastatic liver ... received one of four doses of intratumoral JX-594 (10 8 plaque-forming units [pfu], 3×10 ... maximum-tolerated dose (MTD) and safety of JX-594 treatment. Data were also collected on pharmacokinetics, pharmacodynamics, ... range 1·0–8·0) cycles of JX-594. All patients were evaluable for toxicity. All patients ...
Tópico(s): Viral Infectious Diseases and Gene Expression in Insects
2008 - Elsevier BV | The Lancet Oncology
Abyssinia Expeditionary Force IOR/L/MIL/5/594
0000 - Gale Group | NCCO EuropeAfrica
Ta‐Chiang Liu, Tae-Ho Hwang, Byeong-Ho Park, John C. Bell, David H. Kirn,
JX-594 is a targeted oncolytic poxvirus that is designed to eradicate cancer cells having cell-cycle defects, through ... animal models of hepatocellular carcinoma (HCC), that JX-594 is a promising anticancer agent. We tested JX-594 in three patients with advanced refractory hepatitis B virus (HBV)-associated HCC through intratumoral administration. JX-594 treatment was well-tolerated and resulted in antitumoral ... presence of high levels of neutralizing antibodies. JX-594 replication, its release into the circulation, distant tumor ...
Tópico(s): Viral Infectious Diseases and Gene Expression in Insects
2008 - Elsevier BV | Molecular Therapy